Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23713966 | 0.81 | — | — | |
| SCHEMBL2216049 | 0.77 | HCAR3 (0.34) | AKR1C3AKR1C2POLBLMNAAPAF1 | |
| SCHEMBL31057116 | 0.67 | HDAC6 (0.44) | POLBALDH1A1KDM4EPTGS2 | |
| SCHEMBL908905 | 0.66 | KDM4C (0.40) | AKR1C3AKR1C2LMNAALDH1A1KDM4E | |
| SCHEMBL10429623 | 0.66 | LMNA (0.45) | POLBLMNAAPAF1ALDH1A1GAA | |
| SCHEMBL23713965 | 0.65 | NR1I2 (0.30) | — | |
| SCHEMBL23714080 | 0.64 | L3MBTL1 (0.33) | POLBGAA | |
| SCHEMBL316007 | 0.63 | ALDH1A1 (0.57) | ALDH1A1GAAKDM4EGRNSORT1 | |
| SCHEMBL4662149 | 0.62 | PTGS2 (0.39) | AKR1C3AKR1C2POLBLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL31467467 | 0.62 | ALDH1A1 (0.56) | ALDH1A1GAAKDM4EGRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | AKR1C3 815/4885AKR1C2 421/4885POLB 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.